Meeting
2021 ASCO Annual Meeting
Impact of KRAS mutational status on outcomes in patients with pancreatic cancer (PDAC).
Presenter
Lucy Xiaolu Ma, MD
Princess Margaret Cancer Centre, University Health Network
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4142)
DOI
10.1200/JCO.2021.39.15_suppl.4142
Abstract #
4142
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Gastrointestinal Cancers Symposium
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.
Speaker: Tanios S. Bekaii-Saab, MD
Videos & Slides
2024 ASCO Breakthrough
A potent and selective pan-RAS inhibitor, ADT-1004, targeting complex KRAS mutations for pancreatic cancer.
Speaker: Gary Piazza, PhD
Speaker: Panel Discussion
Videos & Slides
2024 ASCO Gastrointestinal Cancers Symposium
Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors.
Speaker: Jian Li, D.Phil